Posterior reversible encephalopathy syndrome (PRES) associated with SARS-CoV-2 infection in a patient under maintenance haemodialysis: a case report.
End-stage kidney disease
Haemodialysis
Intravascular endothelial cell injury
Posterior reversible encephalopathy syndrome
Status epilepticus
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
29 09 2023
29 09 2023
Historique:
received:
09
03
2023
accepted:
04
09
2023
medline:
5
10
2023
pubmed:
29
9
2023
entrez:
29
9
2023
Statut:
epublish
Résumé
Endothelial dysfunction is common in patients undergoing chronic haemodialysis, and is a major cause of posterior reversible encephalopathy syndrome (PRES). Recently, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been shown to cause endothelial dysfunction by infecting vascular endothelial cells. Several cases of neurological complications in patients without kidney dysfunction, and only a few cases in patients with chronic kidney disease, have been reported in the literature. However, no previous report has yet described PRES associated with SARS-CoV-2 infection among patients undergoing maintenance dialysis. A 54-year-old woman undergoing maintenance haemodialysis was admitted to our hospital for status epilepticus. She had developed end-stage kidney disease (ESKD) secondary to diabetic nephropathy. Seven days prior to admission, she had developed fever and was diagnosed with COVID-19. Subsequently her blood pressure increased from 160/90 mmHg to 190/100 mmHg. On admission, she presented with severe hypertension (> 220/150 mmHg), unconsciousness, and epilepticus. CT tomography revealed no signs of brain haemorrhage. Cranio-spinal fluid (CSF) examination revealed no signs of encephalitis, and CSF polymerase chain reaction (PCR) for SARS-CoV-2 was negative. MRI findings revealed focal T2/FLAIR hyperintensity in the bilateral parietooccipital regions, leading to the diagnosis of PRES. Deep sedation and strict blood pressure control resulted in a rapid improvement of her symptoms, and she was discharged without sequelae. We report the first case of PRES associated with SARS-CoV-2 infection in a patient undergoing maintenance haemodialysis. Patients undergoing maintenance haemodialysis are at high risk of PRES because of several risk factors. SARS-CoV-2 infection causes direct invasion of endothelial cells by binding to angiotensin-converting enzyme 2 (ACE2), initiating cytokine release, and hypercoagulation, leading to vascular endothelial cell injury and increased vascular leakage. In the present case, SARS-CoV-2 infection possibly be associated with the development of PRES.
Sections du résumé
BACKGROUND
Endothelial dysfunction is common in patients undergoing chronic haemodialysis, and is a major cause of posterior reversible encephalopathy syndrome (PRES). Recently, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been shown to cause endothelial dysfunction by infecting vascular endothelial cells. Several cases of neurological complications in patients without kidney dysfunction, and only a few cases in patients with chronic kidney disease, have been reported in the literature. However, no previous report has yet described PRES associated with SARS-CoV-2 infection among patients undergoing maintenance dialysis.
CASE PRESENTATION
A 54-year-old woman undergoing maintenance haemodialysis was admitted to our hospital for status epilepticus. She had developed end-stage kidney disease (ESKD) secondary to diabetic nephropathy. Seven days prior to admission, she had developed fever and was diagnosed with COVID-19. Subsequently her blood pressure increased from 160/90 mmHg to 190/100 mmHg. On admission, she presented with severe hypertension (> 220/150 mmHg), unconsciousness, and epilepticus. CT tomography revealed no signs of brain haemorrhage. Cranio-spinal fluid (CSF) examination revealed no signs of encephalitis, and CSF polymerase chain reaction (PCR) for SARS-CoV-2 was negative. MRI findings revealed focal T2/FLAIR hyperintensity in the bilateral parietooccipital regions, leading to the diagnosis of PRES. Deep sedation and strict blood pressure control resulted in a rapid improvement of her symptoms, and she was discharged without sequelae.
CONCLUSIONS
We report the first case of PRES associated with SARS-CoV-2 infection in a patient undergoing maintenance haemodialysis. Patients undergoing maintenance haemodialysis are at high risk of PRES because of several risk factors. SARS-CoV-2 infection causes direct invasion of endothelial cells by binding to angiotensin-converting enzyme 2 (ACE2), initiating cytokine release, and hypercoagulation, leading to vascular endothelial cell injury and increased vascular leakage. In the present case, SARS-CoV-2 infection possibly be associated with the development of PRES.
Identifiants
pubmed: 37773103
doi: 10.1186/s12882-023-03319-7
pii: 10.1186/s12882-023-03319-7
pmc: PMC10542676
doi:
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
286Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767–83. https://doi.org/10.1016/S1474-4422(20)30221-0 .
doi: 10.1016/S1474-4422(20)30221-0
pubmed: 32622375
pmcid: 7332267
Mishra S, Choueka M, Wang Q, Hu C, Visone S, Silver M, et al. Intracranial hemorrhage in COVID-19 patients. J Stroke Cerebrovasc Dis. 2021;30:105603. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105603 .
doi: 10.1016/j.jstrokecerebrovasdis.2021.105603
pubmed: 33484980
pmcid: 7831866
Motolese F, Ferrante M, Rossi M, Magliozzi A, Sbarra M, Ursini F, et al. Posterior reversible Encephalopathy Syndrome and brain haemorrhage as COVID-19 complication: a review of the available literature. J Neurol. 2021;268:4407–14. https://doi.org/10.1007/s00415-021-10709-0 .
doi: 10.1007/s00415-021-10709-0
pubmed: 34291313
pmcid: 8294241
Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14:914–25. https://doi.org/10.1016/S1474-4422(15)00111-8 .
doi: 10.1016/S1474-4422(15)00111-8
pubmed: 26184985
Gewirtz AN, Gao V, Parauda SCRM. Posterior reversible Encephalopathy Syndrome. Curr Pain Headache Rep. 2021;25:19.
doi: 10.1007/s11916-020-00932-1
pubmed: 33630183
pmcid: 7905767
Hixon AM, Thaker AA, Pelak VS. Persistent visual dysfunction following posterior reversible encephalopathy syndrome due to COVID-19: case series and literature review. Eur J Neurol. 2021;28:3289–302.
doi: 10.1111/ene.14965
pubmed: 34115917
pmcid: 8444757
Lallana S, Chen A, Requena M, Rubiera M, Sanchez A, Siegler JE, et al. Posterior reversible encephalopathy syndrome (PRES) associated with COVID-19. J Clin Neurosci. 2021;88:108–12.
doi: 10.1016/j.jocn.2021.03.028
pubmed: 33992168
pmcid: 7985961
Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol. 2017;264:1608–16.
doi: 10.1007/s00415-016-8377-8
pubmed: 28054130
pmcid: 5533845
Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020;94:55–8. https://doi.org/10.1016/j.ijid.2020.03.062 .
doi: 10.1016/j.ijid.2020.03.062
pubmed: 32251791
pmcid: 7195378
Abenza Abildúa MJ, Atienza S, Carvalho Monteiro G, Erro Aguirre ME, Imaz Aguayo L, Freire Álvarez E, et al. Encephalopathy and encephalitis during acute SARS-CoV-2 infection. Spanish society of Neurology COVID-19 Registry. Neurologia. 2021;36:127–34.
doi: 10.1016/j.nrl.2020.11.013
pubmed: 33549369
pmcid: 7877217
Canney M, Kelly D, Clarkson M. Posterior reversible encephalopathy syndrome in end-stage kidney disease: not strictly posterior or reversible. Am J Nephrol. 2015;41:177–82.
doi: 10.1159/000381316
pubmed: 25871433
Yeahia R, Schefflein J, Chiarolanzio P, Rozenstein A, Gomes W, Ali S, et al. Brain MRI findings in COVID-19 patients with PRES: a systematic review. Clin Imaging. 2022;81:107–13. https://doi.org/10.1016/j.clinimag.2021.10.003 .
doi: 10.1016/j.clinimag.2021.10.003
pubmed: 34700172
Onder AM, Lopez R, Teomete U, Francoeur D, Bhatia R, Knowbi O, et al. Posterior reversible encephalopathy syndrome in the pediatric renal population. Pediatr Nephrol. 2007;22:1921–9.
doi: 10.1007/s00467-007-0578-z
pubmed: 17694337
Assimon MM, Flythe JE. Intradialytic blood pressure abnormalities: the Highs, the Lows and all that lies between. Am J Nephrol. 2015;42:337–50.
doi: 10.1159/000441982
pubmed: 26584275
Chou KJ, Lee PT, Chen CL, Chiou CW, Hsu CY, Chung HM, et al. Physiological changes during hemodialysis in patients with intradialysis hypertension. Kidney Int. 2006;69:1833–8. https://doi.org/10.1038/sj.ki.5000266 .
doi: 10.1038/sj.ki.5000266
pubmed: 16691262
Van Buren PN, Toto R, Inrig JK. Interdialytic ambulatory blood pressure in patients with intradialytic hypertension. Curr Opin Nephrol Hypertens. 2012;21:15–23.
doi: 10.1097/MNH.0b013e32834db3e4
pubmed: 22123207
pmcid: 3282050
Graham BRPG. Posterior reversible encephalopathy syndrome in an adult patient undergoing peritoneal dialysis: a case report and literature review. BMC Nephrol. 2014;13:10.
doi: 10.1186/1471-2369-15-10
Kadikoy H, Haque W, Hoang V, Maliakkal J, Nisbet JAA. Posterior reversible encephalopathy syndrome in a patient with lupus nephritis. Saudi J Kidney Dis Transplant. 2012;23:572–6.
Boyle SM, Berns JS. Erythropoietin and resistant hypertension in CKD. Semin Nephrol. 2014;34:540–9. https://doi.org/10.1016/j.semnephrol.2014.08.008 .
doi: 10.1016/j.semnephrol.2014.08.008
pubmed: 25416663
Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis- stimulating agents (ESA). Clin J Am Soc Nephrol. 2009;4:470–80.
doi: 10.2215/CJN.05040908
pubmed: 19218474
Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34–45.
doi: 10.1038/nri3345
pubmed: 23222502
Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020;76:14–20. https://doi.org/10.1016/j.ejim.2020.04.037 .
doi: 10.1016/j.ejim.2020.04.037
pubmed: 32336612
pmcid: 7167588
Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20:389–91. https://doi.org/10.1038/s41577-020-0343-0 .
doi: 10.1038/s41577-020-0343-0
pubmed: 32439870
pmcid: 7240244
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–8. https://doi.org/10.1016/S0140-6736(20)30937-5 .
doi: 10.1016/S0140-6736(20)30937-5
pubmed: 32325026
pmcid: 7172722
Angeli F, Zappa M, Oliva FM, Spanevello A, Verdecchia P. Blood pressure increase during hospitalization for COVID-19. Eur J Intern Med. 2022;104:110–2.
doi: 10.1016/j.ejim.2022.06.010
pubmed: 35725787
pmcid: 9212702
Urata R, Ikeda K, Yamazaki E, Ueno D, Katayama A, Shin-Ya M, et al. Senescent endothelial cells are predisposed to SARS-CoV-2 infection and subsequent endothelial dysfunction. Sci Rep. 2022;12:1–9. https://doi.org/10.1038/s41598-022-15976-z .
doi: 10.1038/s41598-022-15976-z
Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007;7:803–15.
doi: 10.1038/nri2171
pubmed: 17893694